Open in app

COVID Crisis: Paxlovid is Just-in-Time Innovation.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:

The findings of two Paxlovid clinical studies were released this week, coinciding with the rise of Delta in the US and the quick introduction of the Omicron strain. The timing could not be more ideal for testing the efficacy and safety of a whole new method for combating the virus. Paxlovid, a tiny orally active chemical, was created particularly to combat SARS-CoV-2. It is not a repurposed medication, but rather a derivative of a SARS-fighting precursor. It attaches to the virus's major protease (Mpro), which is an important step before the virus enters high-gear reproduction. Furthermore, unlike vaccination, Paxlovid is an infection intervention, not a primary preventative. Paxlovid is a game-changer; it not only adds a new layer of defense, but it's a one-of-a-kind one that doesn't rely on the human immune system and is unaffected by Omicron or other versions. It's the first medicine created exclusively for SARS-CoV-2, rather than a repurposed chemical, and its efficacy backs up that claim.

(Picture:– The Economic Times)

Reference: -